Across TCGA pan-cancer cohorts, ANKRD39 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ANKRD39 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ANKRD39 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ANKRD39 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

HNSC, UCEC, and CCRCC are the cancer types where ANKRD39 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.950	0.574	.001	57	view →
UCEC	DFS	Median	III,IV	1.000	0.424	.003	20	view →
CCRCC	DFS	Tertile	All	0.681	0.894	.021	8	view →
PDAC	OS	Tertile	III,IV	0.446	0.936	.024	6	view →
LUAD	DFS	Tertile	All	1.000	0.556	.015	2	view →
GBM	DFS	Tertile	All	0.754	0.638	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: ANKRD39 tumor-vs-normal RNA expression · all ANKRD39 data types